Opinion

Video

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

Author(s):

Joyce O’Shaughnessy, MDMelinda L. Telli, MD

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Video content above is prompted by the following question(s):

  • Please discuss your general approach to using neoadjuvant therapy to escalate or deescalate therapy for patients?
Related Videos
Cynthia X. Ma, MD, PhD
A panel of 3 experts on nasopharyngeal carcinoma
Ann H. Partridge, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Alexandra Drakaki, MD, PhD
Adam E. Singer, MD, PhD
Bora Lim, MD, MD Anderson
David Rimm, MD, PhD
Related Content
Paolo Tarantino, MD
September 26th 2024

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

Bora Lim, MD, of MD Anderson Cancer Center
September 25th 2024

Adjuvant Ribociclib Approval Expands Access to CDK4/6 Inhibition in High-Risk HR+/HER2– Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ann H. Partridge, MD, MPH
September 24th 2024

Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer

Susan Galbraith
September 23rd 2024

Dato-DXd Fails to Show OS Benefit in Pretreated HR+/HER2-Low or -Negative Metastatic Breast Cancer